Evotec SE and Secarna Pharmaceuticals GmbH & Co. KG („Secarna“), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide („ASO“) therapies to address challenging or previously undruggable targets via its LNAplus™ platform, have expanded their strategic partnership in the field of ASO-based therapeutics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-secarna-pharmaceuticals-expand-strategic-partnership-in-the-field-of-antisense-drug-discovery-6094
Evotec partner Kazia Therapeutics announces full regulatory approval for Phase I study of EVT801
Evotec partner Kazia Therapeutics Limited today announced that the planned phase I study for EVT801 has received full approval from L’Agence Nationale de Sécurité du Médicament et des Produits de Santé (“ANSM”), the French regulatory agency. The study is expected to open to recruitment by the end of CY2021. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-kazia-therapeutics-announces-full-regulatory-approval-for-phase-i-study-of-evt801-6092
Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration
Evotec SE announced today that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global license for EVT8683 which comes from a broader neurodegeneration collaboration. EVT8683 is a small molecule targeting a key cellular stress response that holds great promise in various neurodegenerative indications and is ready to enter clinical development. The programme originated from a phenotypic screening approach based on Evotec’s leading iPSC platform and reached IND filing within only 5 years. Under an option agreement with Celgene (which is now a Bristol Myers Squibb company), Bristol Myers Squibb has rights to additional programmes in neurodegenerative diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-bristol-myers-squibb-opt-in-of-evt8683-as-the-first-programme-from-ipsc-based-neurodegeneration-collaboration-6090
Symrise Cosmetic Ingredients will strategische Partnerschaft mit Kobo zum Ausbau der Geschäftsbereiche Sonnenschutz und Farben für Kosmetika eingehen
— Erwerb einer Minderheitsbeteiligung von 25 % am US-Unternehmen Kobo Products, Inc. inklusive einer Übereinkunft über die zukünftige Verteilung der Kobo-Anteile
— Symrise wird Vertriebspartner von Kobo für anorganische UV-Filter
— Strategische Partnerschaft soll globale Wachstumsstrategie bei kosmetischen Inhaltsstoffen beschleunigen Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-cosmetic-ingredients-will-strategische-partnerschaft-mit-kobo-zum-ausbau-der-geschaeftsbereic/
Just – Evotec Biologics opens J.POD® 1 US in Redmond, Washington
Evotec SE today announced the opening of the company’s late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD® 1 US) in Redmond, Washington. The innovative cGMP biomanufacturing facility is the final step in Just – Evotec Biologics’ J.DESIGN platform that integrates data analytics and machine learning through all activities involved with the discovery, development, and manufacture of biologics. This includes design of discovery libraries (J.DISCOVERY™), molecules (J.MD™), processes (JP3®) and the manufacturing facility, J.POD®. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-opens-jpodr-1-us-in-redmond-washington-6089
Evotec SE reports first half-year 2021 results and corporate updates
Evotec SE today announced its financial results for the first half-year of 2021: Strong overall performance in the first half of 2021 gaining speed; rapid capacity build-up to foster undisputed growth and future margin expansion; registration statement for proposed offering of American Depositary Shares submitted; guidance for full-year 2021 confirmed; webcast and conference call today at 2.00 pm CEST Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-first-half-year-2021-results-and-corporate-updates-6086
Symrise erzielt kräftiges Umsatz- und Ergebniswachstum im ersten Halbjahr 2021
— Umsatzanstieg auf organischer Basis um 9,7 % — Hohe Profitabilität mit EBITDA-Marge von 22,0 % — Anhebung der Ziele für 2021: Umsatz soll organisch um über 7 % steigen, EBITDA-Marge soll mehr als 21 % betragen Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-erzielt-kraeftiges-umsatz-und-ergebniswachstum-im-ersten-halbjahr-2021/
Symrise Parfümerieschule sucht nächste Generation von Duftkreateuren
— Suche nach Studenten aus Nord- und Lateinamerika
— Zukunft der Branche mit frischen Ideen und modernen Duftlösungen gestalten
— Gemeinschaft fördern, die sich für Vielfalt, Innovation und Nachhaltigkeit einsetzt
— 3+2 Format: 3 Jahre Grundstudium und 2 Jahre weltweiter Einsatz in den Kreativzentren Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-parfuemerieschule-sucht-naechste-generation-von-duftkreateuren/
Evotec SE: Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough
Evotec SE announces that the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough. The underlying molecule is a P2X3 receptor antagonist in Bayer’s clinical development pipeline originating from a former Evotec/Bayer multi-target research alliance. The primary efficacy outcome was met showing a statistically significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound recordings) over placebo after 12 weeks of treatment. The data showed a favourable safety and tolerability profile. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-se-positive-phase-iib-data-for-investigational-p2x3-antagonist-in-patients-with-refractory-chronic-cough-6082
Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares
Evotec SE announces that it confidentially submitted a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares. The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-se-announces-confidential-submission-of-draft-registration-statement-on-form-f-1-with-the-us-securities-and-exchange-commission-for-a-proposed-offering-of-american-depositary-shares-6080